Zimbabwe has declined a substantial US health deal valued at $367m (272 million pounds) over five years due to the United States' demand for sensitive information.
This move became public following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman later explained that the US was demanding access to genetic material for research and profit while was unwilling to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more negotiations to find a deal acceptable to both sides so the nation's critical HIV programme can proceed.
Broader Background
This development comes after a comparable case in Kenya, where a high court blocked a similar deal with the US after legal challenges were filed about the safety of citizens' health data.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
According to reports, 16 nations in Africa have to date signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of access to any medical innovations – such as new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research with no certainty that the resulting innovations would be accessible to our people if a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting structures previously set up via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This framework is designed to ensure that when a nation provides its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how future collaboration could be designed in a way that honours the sovereignty and dignity of both nations."
Medical Community Reaction
Medical experts expressed it understood the official position, but suggested that talks should continue considering a large portion of the country's Aids initiatives were funded by international support.
"Where specific concerns arise, such as those involving information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
This impasse underscores the ongoing debate between receiving much-needed international aid and protecting national sovereignty in an increasingly data-driven world.